LNP LitigationOn March 3, 2026, Arbutus, along with its exclusive licensee, Genevant Sciences ("Genevant"), entered into a settlement agreement to resolve all global patent infringement litigation and patent revocation proceedings involving Moderna. RevenueTotal revenue was $1.0 million for the quarter ended June 30, 2026, compared to $10.7 million for the same period in 2025. Operating ExpensesResearch and development expenses were $2.9 million for the quarter ended June 30, 2026, compared to $5.5 million for the same period in 2025. General and administrative expenses were $3.9 million for the quarter ended June 30, 2026, compared to $3.3 million for the same period in 2025. There were no restructuring costs in the quarter ended June 30, 2026, compared to $0.2 million for the same period in 2025.